Granted Patent
B2
US 12,539,336 · App. 18/620,025 · Granted Feb 3, 2026
Antibody, linkers, payload, conjugates and applications thereof
Inventors:
Dong Yang (Jiang-su, KR); Mingyu Hu (Jiang-su, CN); Yajun Sun (Jiang-su, CN); Paul H. Song (Jiang-su, CN); Hanwen Xu (Jiang-su, CN); Gang Qin (Jiangsu, CN)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to an antibody, a payload and a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.
Claims (4)
1 . An antibody drug conjugate comprising an antibody, a linker, and a payload, wherein the antibody drug conjugate is represented by the following structural formula:
wherein A is an antibody GQhRS7, wherein the amino acid sequence of each heavy chain of the antibody is SEQ ID NO: 30, wherein the amino acid sequence of each light chain of the antibody is SEQ ID NO: 40 modified by deletion of GG in the LPETGG sequence, and wherein the T of the LPET is connected to the linker; and
wherein each occurrence of opSu is independently a structure selected from
2 . A pharmaceutical composition comprising an effective amount of the antibody drug conjugate of claim 1 and a pharmaceutically acceptable carrier, excipient or diluent.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 1, 2024
From: YANG, DONG; HU, MINGYU; SUN, YAJUN; SONG, PAUL H.; XU, HANWEN; QIN, GANG
To: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Reel/Frame 067281/0627 →
Priority Claims (4)
WO PCT/CN2022/106014
· Jul 15, 2022
· international
WO PCT/CN2023/086107
· Apr 4, 2023
· international
WO PCT/CN2023/088115
· Apr 13, 2023
· international
WO PCT/CN2023/107444
· Jul 14, 2023
· international
Continuity (2)
Continuation
PCTCN2023107444
· Jul 14, 2023
References Cited (144)
US 5834476A
· Terasawa et al.
· 1998
[cited by applicant]
US 7517964B2
· Govindan et al.
· 2009
[cited by applicant]
US 9849176B2
· Govindan et al.
· 2017
[cited by applicant]
US 9872923B2
· Grawunder
· 2018
[cited by applicant]
US 9999668B2
· Govindan et al.
· 2018
[cited by applicant]
US 20160193355A1
· Qin et al.
· 2016
[cited by applicant]
US 20210187114A1
· Qin et al.
· 2021
[cited by applicant]
US 20210221907A1
· Hou et al.
· 2021
[cited by applicant]
US 20220378928A1
· Zhu et al.
· 2022
[cited by applicant]
US 20230054458A1
· Yang et al.
· 2023
[cited by applicant]
US 20230101266A1
· Qin et al.
· 2023
[cited by applicant]
US 20230101735A1
· Yang et al.
· 2023
[cited by applicant]
US 20230140397A1
· Ying et al.
· 2023
[cited by applicant]
US 20230165969A1
· Yue et al.
· 2023
[cited by applicant]
US 20230226207A1
· Zhu et al.
· 2023
[cited by applicant]
US 20230241242A1
· Liang et al.
· 2023
[cited by applicant]
US 20230381332A1
· Zhu et al.
· 2023
[cited by applicant]
US 20240066141A1
· Qin et al.
· 2024
[cited by applicant]
AU 2021289927A1
· 2023
[cited by applicant]
AU 2021359457A1
· 2023
[cited by applicant]
CA 3209426
· 2022
[cited by applicant]
CN 104755494A
· 2015
[cited by applicant]
CN 110167355A
· 2019
[cited by applicant]
CN 111689980A
· 2020
[cited by applicant]
CN 112125915
· 2020
[cited by applicant]
CN 2021101599566
· 2021
[cited by applicant]
CN 2021105333044
· 2021
[cited by applicant]
CN 2021107182458
· 2021
[cited by applicant]
CN 202110936768X
· 2021
[cited by applicant]
CN 2021113553309
· 2021
[cited by applicant]
CN 113816969A
· 2021
[cited by applicant]
CN 113827736A
· 2021
[cited by applicant]
CN 113943310A
· 2022
[cited by applicant]
CN 114569739A
· 2022
[cited by applicant]
CN 115103691A
· 2022
[cited by applicant]
EP 0495432A1
· 1992
[cited by applicant]
EP 0700914A1
· 1996
[cited by applicant]
EP 3725798A1
· 2020
[cited by applicant]
EP 4095148A1
· 2022
[cited by applicant]
EP 4129345A1
· 2023
[cited by applicant]
EP 4130006A1
· 2023
[cited by applicant]
EP 4130045A1
· 2023
[cited by applicant]
EP 4162954A1
· 2023
[cited by applicant]
JP 3359955B2
· 1994
[cited by applicant]
WO WO2003074566A2
· 2003
[cited by applicant]
WO WO2005051976A2
· 2005
[cited by applicant]
WO WO2010087994A2
· 2010
[cited by applicant]
WO WO2014057687A1
· 2014
[cited by applicant]
WO WO2014177042A1
· 2014
[cited by applicant]
WO WO2015047510A1
· 2015
[cited by applicant]
WO WO2015115091A1
· 2015
[cited by applicant]
WO WO2015165413A1
· 2015
[cited by applicant]
WO WO2018112253A1
· 2018
[cited by applicant]
WO WO2020016662A2
· 2020
[cited by applicant]
WO WO2020063673A1
· 2020
[cited by applicant]
WO WO2020063676A1
· 2020
[cited by applicant]
WO WO2021007435A1
· 2021
[cited by applicant]
WO WO2021052402A1
· 2021
[cited by applicant]
WO WO2021115426A1
· 2021
[cited by applicant]
WO WO2021147993A1
· 2021
[cited by applicant]
WO WO2021136475A1
· 2021
[cited by examiner]
WO WO2021136483A1
· 2021
[cited by examiner]
WO WO2021190581A1
· 2021
[cited by applicant]
WO WO2021190583A1
· 2021
[cited by applicant]
WO WO2021190586A1
· 2021
[cited by applicant]
WO WO2021190602A1
· 2021
[cited by applicant]
WO WO2021249228A1
· 2021
[cited by applicant]
WO WO2022056696A1
· 2022
[cited by applicant]
WO WO2022068878A1
· 2022
[cited by applicant]
WO WO2022078259A1
· 2022
[cited by applicant]
WO WO2022078260A1
· 2022
[cited by applicant]
WO WO2022078279A1
· 2022
[cited by applicant]
WO WO2022099762A1
· 2022
[cited by applicant]
WO PCTCN2022101787
· 2022
[cited by applicant]
WO WO2022133722A1
· 2022
[cited by applicant]
WO WO2022159984A1
· 2022
[cited by examiner]
WO WO2022160156A1
· 2022
[cited by applicant]
WO WO2022166762A1
· 2022
[cited by applicant]
WO WO2022170676A1
· 2022
[cited by applicant]
WO WO2022188740A1
· 2022
[cited by applicant]
WO WO2022188743A1
· 2022
[cited by applicant]
WO WO2022219331A1
· 2022
[cited by applicant]
WO WO2022218331A1
· 2022
[cited by examiner]
WO WO2022236136A1
· 2022
[cited by applicant]
WO WO2022253284A1
· 2022
[cited by applicant]
WO PCTCN2023081140
· 2023
[cited by applicant]
WO PCTCN2023088092
· 2023
[cited by applicant]
WO WO2023088235A1
· 2023
[cited by examiner]
WO WO2023143319A1
· 2023
[cited by applicant]
WO WO2023143320A1
· 2023
[cited by applicant]
WO WO2024012566A2
· 2024
[cited by applicant]
WO WO2024002154A1
· 2024
[cited by examiner]
WO WO2024012569A1
· 2024
[cited by applicant]
Anti-Trop-2 antibody hRS7 VH region Seq Id 58, Supplemental Complex Repository for Examiners (SCORE): (Year: 2021).
[cited by examiner]
Anti-Trop-2 antibody hRS7 VL region, Seq Id 11; Supplemental Complex Repository for Examiners (Year: 2021).
[cited by examiner]
CAS No. 2019_1191462_1491917839_1, Entered Jun. 20, 2019.
[cited by applicant]
Polson et al. (2009) “Antibody Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection,”
[cited by applicant]
Ta et al. (2012) “Enzymatic Antibody Tagging: Toward a Universal Biocompatible Targeting Tool”
[cited by applicant]
U.S. Appl. No. 18/053,459 U.S. Pat. No. 11,814,394, filed Nov. 8, 2022 (Nov. 14, 2023), Dong Yang (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
U.S. Appl. No. 18/453,748 (US 2024/0018159 A1), filed Aug. 22, 2023 (Jan. 18, 2024), Dong Yang (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
P230101858, Jul. 15, 2022, Dong Yang (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
PCT/CN2022/106014, Jul. 15, 2022, Dong Yang (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
PCT/CN2023/086107, Apr. 3, 2023, Dong Yang (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
PCT/CN2023/088115, Apr. 13, 2023, Dong Yang (GeneQuantum Helathcare (Suzhou) Co., Ltd.).
[cited by applicant]
PCT/CN2023/107444 (WO 2024/012566 A2), filed Jul. 14, 2023 (Jan. 18, 2024), Dong Yang (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
PCT/CN2021/130896, Nov. 16, 2021, ,Gang Qin (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
PCT/CN2022/131904 (WO 2023/088235 A1), filed Nov. 15, 2022 (May 25, 2023), Gang Qin (GeneQuantum Healthcare (Suzhou) Co., Ltd.).
[cited by applicant]
U.S. Appl. No. 18/711,006, Qin et al.
[cited by applicant]
Sugimori, M. et al., “Synthesis and Antitumor Activity of Ring A- and F-Modified Hexacyclic Camptothecin Analogues,” Journal of Medicinal Chemistry, 1998, 41, 2308-2318.
[cited by applicant]
Tamura, A. et al., “Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2,” Cancer Science, 2007, 98 (2), 231-239.
[cited by applicant]
Wani, M. et al., “Plant Antitumor Agents. 23.1 Synthesis and Antileukemic Activity of Camptothecin Analogues,” Journal of Medicinal Chemistry, 1986, 29, 2358-2363.
[cited by applicant]
Yaegashi, T. et al., “Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives. A-Ring-Substituted 7-Ehtylcamptothecins and Their E-Ring-Modified Water-Soluble Derivatives,” Chemical and Pharmaceutical Bulleti…
[cited by applicant]
U.S. Appl. No. 18/879,386, Qin et al.
[cited by applicant]